Charles River Laboratories International (CRL) EV/FCF: History & Chart

Charles River Laboratories International, Inc.(CRL)

Medical - Diagnostics & Research · Wilmington, MA

$277.05-3.71 (-1.32%)

Delayed quote: Sep 9, 2026, 10:35 AM EDT

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Wilmington, MA

19,000 employees

www.criver.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Birgit Girshick

View full financials

CRL EV/FCF Ratio Metrics

EV/FCF RATIO

44.38x

EV/FCF RATIO AVG TTM

24.89x

EV/FCF RATIO AVG 3Y

28.29x

EV/FCF RATIO AVG 5Y

34.83x

EV/FCF RATIO AVG 10Y

32.05x

EV/FCF RATIO AVG 15Y

27.09x

EV/FCF RATIO AVG 20Y

27.11x

CURRENT VS TTM AVG

+78.28%

CURRENT VS 3Y AVG

+56.88%

CURRENT VS 5Y AVG

+27.44%

CURRENT VS 10Y AVG

+38.49%

CURRENT VS 15Y AVG

+63.80%

CURRENT VS 20Y AVG

+63.68%

SECTOR MEDIAN · HEALTHCARE

24.79x

median of 83 covered companies

CURRENT VS SECTOR MEDIAN

+79.02%

vs the sector median at left

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Charles River Laboratories International, Inc. (CRL)	$13.34B	44.38x	24.89x	28.29x	34.83x
Revvity, Inc. (RVTY)vs ›	$13.69B	29.53x	27.61x	259.45x	164.89x
The Cooper Companies, Inc. (COO)vs ›	$13.10B	27.25x	35.84x	79.44x	64.95x
Baxter International Inc. (BAX)vs ›	$12.94B	30.08x	51.55x	50.40x	47.11x
Penumbra, Inc. (PEN)vs ›	$12.61B	59.08x	68.99x	1098.24x	1679.49x
Exelixis, Inc. (EXEL)vs ›	$14.32B	12.58x	14.81x	26.46x	25.14x
Encompass Health Corporation (EHC)vs ›	$11.88B	36.08x	32.12x	42.14x	48.08x
DaVita Inc. (DVA)vs ›	$11.68B	13.68x	18.11x	17.69x	17.89x
Solventum Corporation (SOLV)vs ›	$15.46B	N/A	157.09x	88.54x	88.54x
Bio-Techne Corporation (TECH)vs ›	$11.32B	43.22x	39.70x	44.78x	48.67x

NAME

MARKET CAP

EV/FCF RATIO

TTM

Charles River Laboratories International, Inc. (CRL)

$13.34B

44.38x

24.89x

28.29x

34.83x

Revvity, Inc. (RVTY)vs ›

$13.69B

29.53x

27.61x

259.45x

164.89x

The Cooper Companies, Inc. (COO)vs ›

$13.10B

27.25x

35.84x

79.44x

64.95x

Baxter International Inc. (BAX)vs ›

$12.94B

30.08x

51.55x

50.40x

47.11x

Penumbra, Inc. (PEN)vs ›

$12.61B

59.08x

68.99x

1098.24x

1679.49x

Exelixis, Inc. (EXEL)vs ›

$14.32B

12.58x

14.81x

26.46x

25.14x

Encompass Health Corporation (EHC)vs ›

$11.88B

36.08x

32.12x

42.14x

48.08x

DaVita Inc. (DVA)vs ›

$11.68B

13.68x

18.11x

17.69x

17.89x

Solventum Corporation (SOLV)vs ›

$15.46B

N/A

157.09x

88.54x

Bio-Techne Corporation (TECH)vs ›

$11.32B

43.22x

39.70x

44.78x

48.67x

EV/FCF Ratio FAQ

What is the EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?

The EV/FCF ratio for CRL stock is 44.38x.

Is Charles River Laboratories International, Inc.'s EV/FCF ratio high or low?

The EV/FCF ratio of 44.38x is 27% above its 5-year average of 34.83x, around the middle of its 5-year range (15.21x–58.96x).

What is the TTM average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?

The TTM average EV/FCF ratio for CRL stock is 24.89x.

What is the 3Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?

The 3Y average EV/FCF ratio for CRL stock is 28.29x.

What is the 5Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?

The 5Y average EV/FCF ratio for CRL stock is 34.83x.

What is the 10Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?

The 10Y average EV/FCF ratio for CRL stock is 32.05x.

What is the 15Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?

The 15Y average EV/FCF ratio for CRL stock is 27.09x.

What is the 20Y average EV/FCF ratio for Charles River Laboratories International, Inc. (CRL)?

The 20Y average EV/FCF ratio for CRL stock is 27.11x.

DATE	EV/FCF RATIO
2026-09-08	44.38x
2026-09-04	45.40x
2026-09-03	46.03x
2026-09-02	45.82x
2026-09-01	44.59x
2026-08-31	45.36x
2026-08-28	45.79x
2026-08-27	46.43x
2026-08-26	46.26x
2026-08-25	46.59x
2026-08-24	46.71x
2026-08-21	46.27x
2026-08-20	45.78x
2026-08-19	45.59x
2026-08-18	44.18x
2026-08-17	45.15x
2026-08-14	44.29x
2026-08-13	44.45x
2026-08-12	44.86x
2026-08-11	44.55x
2026-08-10	43.89x
2026-08-07	42.65x
2026-08-06	42.39x
2026-08-05	41.76x
2026-08-04	36.61x
2026-08-03	36.20x
2026-07-31	36.41x
2026-07-30	36.67x
2026-07-29	36.69x
2026-07-28	37.40x
2026-07-27	35.38x
2026-07-24	35.67x
2026-07-23	36.00x
2026-07-22	34.68x
2026-07-21	34.77x
2026-07-20	34.81x
2026-07-17	35.39x
2026-07-16	35.99x
2026-07-15	35.87x
2026-07-14	36.25x
2026-07-13	36.06x
2026-07-10	36.52x
2026-07-09	36.54x
2026-07-08	35.34x
2026-07-07	35.93x
2026-07-06	36.27x
2026-07-02	36.18x
2026-07-01	35.98x
2026-06-30	35.69x
2026-06-29	35.54x
2026-06-26	34.31x
2026-06-25	33.93x
2026-06-24	32.60x
2026-06-23	30.66x
2026-06-22	30.03x
2026-06-18	30.46x
2026-06-17	30.13x
2026-06-16	30.44x
2026-06-15	30.90x
2026-06-12	30.78x
2026-06-11	30.85x
2026-06-10	30.63x
2026-06-09	31.07x
2026-06-08	30.64x
2026-06-05	30.01x
2026-06-04	30.56x
2026-06-03	29.82x
2026-06-02	29.19x
2026-06-01	30.10x
2026-05-29	29.93x
2026-05-28	30.01x
2026-05-27	27.90x
2026-05-26	26.93x
2026-05-22	27.37x
2026-05-21	27.19x
2026-05-20	26.84x
2026-05-19	26.39x
2026-05-18	26.08x
2026-05-15	26.19x
2026-05-14	27.23x
2026-05-13	27.69x
2026-05-12	28.42x
2026-05-11	28.40x
2026-05-08	29.54x
2026-05-07	30.05x
2026-05-06	22.75x
2026-05-05	23.10x
2026-05-04	21.86x
2026-05-01	21.24x
2026-04-30	21.35x
2026-04-29	21.05x
2026-04-28	21.33x
2026-04-27	21.75x
2026-04-24	21.62x
2026-04-23	21.42x
2026-04-22	23.04x
2026-04-21	22.88x
2026-04-20	23.11x
2026-04-17	22.95x
2026-04-16	22.30x
2026-04-15	22.64x
2026-04-14	22.52x
2026-04-13	22.43x
2026-04-10	22.17x
2026-04-09	22.16x
2026-04-08	22.12x
2026-04-07	21.59x
2026-04-06	21.47x
2026-04-02	22.01x
2026-04-01	22.10x
2026-03-31	21.87x
2026-03-30	20.66x
2026-03-27	20.61x
2026-03-26	21.17x
2026-03-25	21.25x
2026-03-24	20.61x
2026-03-23	20.50x
2026-03-20	20.08x
2026-03-19	20.03x
2026-03-18	20.41x
2026-03-17	20.09x
2026-03-16	19.93x
2026-03-13	20.26x
2026-03-12	19.99x
2026-03-11	21.53x
2026-03-10	21.39x
2026-03-09	22.30x
2026-03-06	22.06x
2026-03-05	22.71x
2026-03-04	22.55x
2026-03-03	22.18x
2026-03-02	22.45x
2026-02-27	22.44x
2026-02-26	22.15x
2026-02-25	21.41x
2026-02-24	21.26x
2026-02-23	21.02x
2026-02-20	21.53x
2026-02-19	21.09x
2026-02-18	20.50x
2026-02-17	18.87x
2026-02-13	19.13x
2026-02-12	18.89x
2026-02-11	19.55x
2026-02-10	20.93x
2026-02-09	21.34x
2026-02-06	21.66x
2026-02-05	21.16x
2026-02-04	22.79x
2026-02-03	22.77x
2026-02-02	23.84x
2026-01-30	23.59x
2026-01-29	23.70x
2026-01-28	24.17x
2026-01-27	24.42x
2026-01-26	24.67x
2026-01-23	24.42x
2026-01-22	24.82x
2026-01-21	25.07x
2026-01-20	24.29x
2026-01-16	24.43x
2026-01-15	24.77x
2026-01-14	24.13x
2026-01-13	24.37x
2026-01-12	24.35x
2026-01-09	24.54x
2026-01-08	24.05x
2026-01-07	24.16x
2026-01-06	24.10x
2026-01-05	23.40x
2026-01-02	22.86x
2025-12-31	22.59x
2025-12-30	22.82x
2025-12-29	22.93x
2025-12-26	22.97x
2025-12-24	22.93x
2025-12-23	22.90x
2025-12-22	22.91x
2025-12-19	22.37x
2025-12-18	22.08x
2025-12-17	22.27x
2025-12-16	22.21x
2025-12-15	22.47x
2025-12-12	22.01x
2025-12-11	22.13x
2025-12-10	22.17x
2025-12-09	21.37x
2025-12-08	21.47x
2025-12-05	21.21x
2025-12-04	21.19x
2025-12-03	21.25x
2025-12-02	20.35x
2025-12-01	20.47x
2025-11-28	20.65x
2025-11-26	20.73x
2025-11-25	20.64x
2025-11-24	19.95x
2025-11-21	19.70x
2025-11-20	19.19x
2025-11-19	19.15x
2025-11-18	19.23x
2025-11-17	19.25x
2025-11-14	19.71x
2025-11-13	19.84x
2025-11-12	20.05x
2025-11-11	20.23x
2025-11-10	19.82x
2025-11-07	19.74x
2025-11-06	19.99x
2025-11-05	19.70x
2025-11-04	19.66x
2025-11-03	19.75x
2025-10-31	19.85x
2025-10-30	19.77x
2025-10-29	19.86x
2025-10-28	20.52x
2025-10-27	21.15x
2025-10-24	21.30x
2025-10-23	20.78x
2025-10-22	20.44x
2025-10-21	20.55x
2025-10-20	20.20x
2025-10-17	19.72x
2025-10-16	19.41x
2025-10-15	19.05x
2025-10-14	19.00x
2025-10-13	19.05x
2025-10-10	18.74x
2025-10-09	19.17x
2025-10-08	19.29x
2025-10-07	19.00x
2025-10-06	19.41x
2025-10-03	19.62x
2025-10-02	19.45x
2025-10-01	19.03x
2025-09-30	17.84x
2025-09-29	17.03x
2025-09-26	17.16x
2025-09-25	16.91x
2025-09-24	17.24x
2025-09-23	17.31x
2025-09-22	17.62x
2025-09-19	17.75x
2025-09-18	17.88x
2025-09-17	17.52x
2025-09-16	17.42x
2025-09-15	17.48x
2025-09-12	17.53x
2025-09-11	18.12x
2025-09-10	17.57x
2025-09-09	17.92x
2025-09-08	18.31x
2025-09-05	18.48x
2025-09-04	18.34x
2025-09-03	18.34x
2025-09-02	18.25x
2025-08-29	18.42x
2025-08-28	18.41x
2025-08-27	18.38x
2025-08-26	18.46x

DATE

EV/FCF RATIO

2026-09-08

44.38x

2026-09-04

45.40x

2026-09-03

46.03x

2026-09-02

45.82x

2026-09-01

44.59x

2026-08-31

45.36x

2026-08-28

45.79x

2026-08-27

46.43x

2026-08-26

46.26x

2026-08-25

46.59x

2026-08-24

46.71x

2026-08-21

46.27x

2026-08-20

45.78x

2026-08-19

45.59x

2026-08-18

44.18x

2026-08-17

45.15x

2026-08-14

44.29x

2026-08-13

44.45x

2026-08-12

44.86x

2026-08-11

44.55x

2026-08-10

43.89x

2026-08-07

42.65x

2026-08-06

42.39x

2026-08-05

41.76x

2026-08-04

36.61x

2026-08-03

36.20x

2026-07-31

36.41x

2026-07-30

36.67x

2026-07-29

36.69x

2026-07-28

37.40x

2026-07-27

35.38x

2026-07-24

35.67x

2026-07-23

36.00x

2026-07-22

34.68x

2026-07-21

34.77x

2026-07-20

34.81x

2026-07-17

35.39x

2026-07-16

35.99x

2026-07-15

35.87x

2026-07-14

36.25x

2026-07-13

36.06x

2026-07-10

36.52x

2026-07-09

36.54x

2026-07-08

35.34x

2026-07-07

35.93x

2026-07-06

36.27x

2026-07-02

36.18x

2026-07-01

35.98x

2026-06-30

35.69x

2026-06-29

35.54x

2026-06-26

34.31x

2026-06-25

33.93x

2026-06-24

32.60x

2026-06-23

30.66x

2026-06-22

30.03x

2026-06-18

30.46x

2026-06-17

30.13x

2026-06-16

30.44x

2026-06-15

30.90x

2026-06-12

30.78x

2026-06-11

30.85x

2026-06-10

30.63x

2026-06-09

31.07x

2026-06-08

30.64x

2026-06-05

30.01x

2026-06-04

30.56x

2026-06-03

29.82x

2026-06-02

29.19x

2026-06-01

30.10x

2026-05-29

29.93x

2026-05-28

30.01x

2026-05-27

27.90x

2026-05-26

26.93x

2026-05-22

27.37x

2026-05-21

27.19x

2026-05-20

26.84x

2026-05-19

26.39x

2026-05-18

26.08x

2026-05-15

26.19x

2026-05-14

27.23x

2026-05-13

27.69x

2026-05-12

28.42x

2026-05-11

28.40x

2026-05-08

29.54x

2026-05-07

30.05x

2026-05-06

22.75x

2026-05-05

23.10x

2026-05-04

21.86x

2026-05-01

21.24x

2026-04-30

21.35x

2026-04-29

21.05x

2026-04-28

21.33x

2026-04-27

21.75x

2026-04-24

21.62x

2026-04-23

21.42x

2026-04-22

23.04x

2026-04-21

22.88x

2026-04-20

23.11x

2026-04-17

22.95x

2026-04-16

22.30x

2026-04-15

22.64x

2026-04-14

22.52x

2026-04-13

22.43x

2026-04-10

22.17x

2026-04-09

22.16x

2026-04-08

22.12x

2026-04-07

21.59x

2026-04-06

21.47x

2026-04-02

22.01x

2026-04-01

22.10x

2026-03-31

21.87x

2026-03-30

20.66x

2026-03-27

20.61x

2026-03-26

21.17x

2026-03-25

21.25x

2026-03-24

20.61x

2026-03-23

20.50x

2026-03-20

20.08x

2026-03-19

20.03x

2026-03-18

20.41x

2026-03-17

20.09x

2026-03-16

19.93x

2026-03-13

20.26x

2026-03-12

19.99x

2026-03-11

21.53x

2026-03-10

21.39x

2026-03-09

22.30x

2026-03-06

22.06x

2026-03-05

22.71x

2026-03-04

22.55x

2026-03-03

22.18x

2026-03-02

22.45x

2026-02-27

22.44x

2026-02-26

22.15x

2026-02-25

21.41x

2026-02-24

21.26x

2026-02-23

21.02x

2026-02-20

21.53x

2026-02-19

21.09x

2026-02-18

20.50x

2026-02-17

18.87x

2026-02-13

19.13x

2026-02-12

18.89x

2026-02-11

19.55x

2026-02-10

20.93x

2026-02-09

21.34x

2026-02-06

21.66x

2026-02-05

21.16x

2026-02-04

22.79x

2026-02-03

22.77x

2026-02-02

23.84x

2026-01-30

23.59x

2026-01-29

23.70x

2026-01-28

24.17x

2026-01-27

24.42x

2026-01-26

24.67x

2026-01-23

24.42x

2026-01-22

24.82x

2026-01-21

25.07x

2026-01-20

24.29x

2026-01-16

24.43x

2026-01-15

24.77x

2026-01-14

24.13x

2026-01-13

24.37x

2026-01-12

24.35x

2026-01-09

24.54x

2026-01-08

24.05x

2026-01-07

24.16x

2026-01-06

24.10x

2026-01-05

23.40x

2026-01-02

22.86x

2025-12-31

22.59x

2025-12-30

22.82x

2025-12-29

22.93x

2025-12-26

22.97x

2025-12-24

22.93x

2025-12-23

22.90x

2025-12-22

22.91x

2025-12-19

22.37x

2025-12-18

22.08x

2025-12-17

22.27x

2025-12-16

22.21x

2025-12-15

22.47x

2025-12-12

22.01x

2025-12-11

22.13x

2025-12-10

22.17x

2025-12-09

21.37x

2025-12-08

21.47x

2025-12-05

21.21x

2025-12-04

21.19x

2025-12-03

21.25x

2025-12-02

20.35x

2025-12-01

20.47x

2025-11-28

20.65x

2025-11-26

20.73x

2025-11-25

20.64x

2025-11-24

19.95x

2025-11-21

19.70x

2025-11-20

19.19x

2025-11-19

19.15x

2025-11-18

19.23x

2025-11-17

19.25x

2025-11-14

19.71x

2025-11-13

19.84x

2025-11-12

20.05x

2025-11-11

20.23x

2025-11-10

19.82x

2025-11-07

19.74x

2025-11-06

19.99x

2025-11-05

19.70x

2025-11-04

19.66x

2025-11-03

19.75x

2025-10-31

19.85x

2025-10-30

19.77x

2025-10-29

19.86x

2025-10-28

20.52x

2025-10-27

21.15x

2025-10-24

21.30x

2025-10-23

20.78x

2025-10-22

20.44x

2025-10-21

20.55x

2025-10-20

20.20x

2025-10-17

19.72x

2025-10-16

19.41x

2025-10-15

19.05x

2025-10-14

19.00x

2025-10-13

19.05x

2025-10-10

18.74x

2025-10-09

19.17x

2025-10-08

19.29x

2025-10-07

19.00x

2025-10-06

19.41x

2025-10-03

19.62x

2025-10-02

19.45x

2025-10-01

19.03x

2025-09-30

17.84x

2025-09-29

17.03x

2025-09-26

17.16x

2025-09-25

16.91x

2025-09-24

17.24x

2025-09-23

17.31x

2025-09-22

17.62x

2025-09-19

17.75x

2025-09-18

17.88x

2025-09-17

17.52x

2025-09-16

17.42x

2025-09-15

17.48x

2025-09-12

17.53x

2025-09-11

18.12x

2025-09-10

17.57x

2025-09-09

17.92x

2025-09-08

18.31x

2025-09-05

18.48x

2025-09-04

18.34x

2025-09-03

18.34x

2025-09-02

18.25x

2025-08-29

18.42x

2025-08-28

18.41x

2025-08-27

18.38x

2025-08-26

18.46x

EV/FCF Ratio: 44.38x

CRL EV/FCF Ratio Chart

CRL Average EV/FCF Ratio Chart

CRL Current vs Average EV/FCF Ratio Chart

CRL EV/FCF Ratio Metrics

CRL Competitors' EV/FCF Ratio

Cash Flow Valuation Comparison

EV/FCF Ratio Formula & Definition

EV/FCF Ratio FAQ

CRL EV/FCF Ratio History

Related Metrics